1. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Issue 8 (August 2021) Authors: Rojas, Jhon; de Lazzari, Elisa; Negredo, Eugenia; Domingo, Pere; Tiraboschi, Juan; Ribera, Esteve; Abdulghani, Nadia; Puig, Jordi; Mateo, Maria G; Podzamczer, Daniel; Gutierrez, Maria M; Paredes, Roger; Clotet, Bonaventura; Gatell, Jose M; Blanco, Jose L; Martínez, Esteban Journal: Lancet Issue: Volume 8:Issue 8(2021) Page Start: e463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Issue 11 (November 2021) Authors: Nomah, Daniel K; Reyes-Urueña, Juliana; Díaz, Yesika; Moreno, Sergio; Aceiton, Jordi; Bruguera, Andreu; Vivanco-Hidalgo, Rosa M; Llibre, Josep M; Domingo, Pere; Falcó, Vicenç; Imaz, Arkaitz; Cortés, Cristina; Force, Lluís; Letang, Emili; Vilaró, Ingrid; Casabona, Jordi; Miro, Jose M; Muntada, Est... Journal: Lancet Issue: Volume 8:Issue 11(2021) Page Start: e701 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗